JERSEY CITY: Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, said Sunday it will acquire Organon & Co. for $14 per share in an all-cash deal valued at $11.75 billion, a transaction that would vault the Mumbai-based company into the ranks of the world’s top 25 pharmaceutical firms.
The boards of both companies have approved the agreement, which is expected to close in early 2027, pending regulatory clearances and a shareholder vote by Organon investors, according to a statement.
Organon, a New Jersey-based healthcare company spun off from Merck in 2021, reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for the fiscal year ended Dec. 31, 2025. The company markets more than 70 products across women’s health and general medicines — including biosimilars — in roughly 140 countries.
The deal would give Sun Pharma its first significant foothold in biosimilars, making the combined entity the world’s seventh-largest biosimilar player. The merged company would also become a top-three competitor in global women’s health, operate in 150 countries, and carry a combined net debt-to-EBITDA ratio of 2.3 times after closing.
“This transaction represents a significant opportunity for Sun Pharma to build on its vision,” said Dilip Shanghvi, Sun Pharma’s executive chairman, adding that Organon’s “portfolio, capabilities and global reach are highly complementary to our own.”
Organon Executive Chair Carrie Cox said the company’s board concluded after a review of strategic alternatives that the all-cash offer provides “compelling and immediate value” to stockholders.
Sun Pharma plans to finance the purchase through a combination of cash on hand and committed bank financing. Citigroup, JPMorgan Chase and MUFG Bank are serving as financing banks for the deal. J.P. Morgan Securities and Jefferies are advising Sun Pharma, while Morgan Stanley and Goldman Sachs are advising Organon.
Organon carries $8.6 billion in debt and held $574 million in cash as of the end of 2025. The company said proceeds from a recent product divestiture — which generated a $440 million upfront payment — will further bolster its balance sheet ahead of closing.
The transaction will be structured as a merger of Organon with a Sun Pharma subsidiary, with Organon surviving as the continuing entity.
Editor’s Analysis
This is a landmark outbound acquisition by an Indian pharma giant — and one that carries both strategic logic and meaningful execution risk. Sun Pharma is essentially buying scale and geography in a single stroke: Organon’s sprawling 140-country footprint and its entrenched physician relationships in women’s health and branded generics are not assets Sun could easily build organically.
The biosimilars entry is the sleeper story here. Sun Pharma has watched rivals build biosimilar pipelines for years; this deal leapfrogs that effort entirely, landing the combined company at No. 7 globally. That ranking is strategically valuable as U.S. and European payers continue to push biosimilar adoption aggressively.
The challenge will be the balance sheet. Organon brought $8.6 billion in debt into this marriage, and the post-close net debt-to-EBITDA ratio of 2.3x — while manageable — leaves limited room for error. Sun Pharma will need to execute a clean integration while delivering the “significant revenue upside” synergies it has flagged to investors.
Organon stockholders should welcome the certainty of $14 per share in cash after the company’s stock struggled post-spinoff. For Sun Pharma shareholders, the long-term thesis is compelling — but patience through a complex, multi-jurisdiction integration will be required.